TumorGlow Intraoperative Molecular Imaging (IMI)

• Status: Not yet recruiting
• Trial end date: 2026-01-14
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania

Criteria

Inclusion Criteria:

• Adult patients 18 years of age or older.

• Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment.

• Good operative candidate as determined by the treating physician and/or multidisciplinary team.

• Subject capable of giving informed consent.

Exclusion Criteria:

• Subject unable to participate in the consent process.

• Vulnerable population including pregnant women, prisoners, and children.

• History of uncontrolled hypertension (e.g., history of an ER admission for hypertensive crisis or ≥ 3 blood pressure medications)

• Patients with a self-reported history of iodide allergies.